Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 291-299

  Kirstein, Mark N ^a   Brundage, Richard C ^b   Moore, Megan M ^b   Williams, Brent W ^b   Hillman, Lisa A ^b   Dagit, Jason W ^a,b   Fisher, James E ^a,b   Marker, Paul H ^c   Kratzke, Robert A ^a   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bioreactor; Gemcitabine; MDA MB 231 cells; Pharmacokinetics; SubG1

Indexed keywords

GEMCITABINE;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BIOREACTOR; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DEGRADATION; DRUG EXPOSURE; DRUG INFUSION; FLOW CYTOMETRY; HARVEST PERIOD; HUMAN; HUMAN CELL; INFUSION RATE; MONOLAYER CULTURE; NICK END LABELING; PRIORITY JOURNAL; TUMOR CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BIOREACTORS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 36349012411     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0474-z     Document Type: Article

References (37)

1. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10(20):6956-6961
2. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58(19):4349-4357
3. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9(13):5000-5008
4. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC (2002) Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 277(7):5453-5459
5. Bouffard DY, Laliberte J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45(9):1857-1861
6. Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC (2002) Characterization of human UMP/CMP kinase and its phosphorylation of d- and l-form deoxycytidine analogue monophosphates. Cancer Res 62(6):1624-1631
7. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W, (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38(4):567-572
8. Ross DD, Cuddy DP (1994) Molecular effects of 2′,2′- difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48(8):1619-1630
9. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51(22):6110-6117
10. Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7-13
11. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491-498
12. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18(14):2780-2787
13. Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF (2005) Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93(1):35-40
14. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402-3408
15. Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D (2006) Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat 96(3):217-225
16. Chen M, Hough AM, Lawrence TS (2000) The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 45(5):369-374
17. Matranga CB, Shapiro GI (2002) Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 62(6):1707-1717
18. Twentyman PR, Luscombe M (1987) A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56(3):279-285
19. Hill A (1913) Biochem J 7:471-480
20. D'Argenio DZaS A (1997) ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. In: Biomedical Simulations Resource, Los Angeles
21. Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF (2006) Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66(23):11305-11313
22. Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de Boeck G, de Bruijn E, Verweij J (2002) The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13(6):583-593
23. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17(7):2190-2197
24. Ferrari M, Fornasiero MC, Isetta AM (1990) MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 131(2):165-172
25. Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56(1):1-10
26. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35(5):796-807
27. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, Ubezio P (2001) Cell cycle effects of gemcitabine. Int J Cancer 93(3):401-408
28. Ng SSW, Tsao MS, Chow S, Hedley DW (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60(19):5451-5455
29. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Van Bockstaele DR, Vermeulen K, Lenjou M, de Pooter CM, Vermorken JB, Lardon F (2003) Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57(4):1075-1083
30. Perabo FG, Lindner H, Schmidt D, Huebner D, Blatter J, Fimmers R, Muller SC, Albers P (2003) Preclinical evaluation of gemcitabine/paclitaxel- interactions in human bladder cancer lines. Anticancer Res 23(6C):4805-4814
31. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA (2005) Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res Treat 90(1):25-31
32. Chandler NM, Canete JJ, Callery MP (2004) Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg 8(8):1072-1078
33. Serrano MJ, Sanchez-Rovira P, Algarra I, Jaen A, Lozano A, Gaforio JJ (2002) Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. Jpn J Cancer Res 93(5):559-566
34. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, Anton A, Rios MJ, Palacios J, Moreno-Bueno G (2006) Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 102(2):157-172
35. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62
36. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W (2001) S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61(3):1065-1072
37. Huang P, Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36(3):181-188